Optimeos Life Sciences has developed an innovative nanoparticle platform designed to enhance the delivery of RNA and DNA therapeutics, addressing key challenges in the field. This platform offers tunable immunogenicity, allowing for reduced immune activation in protein replacement therapies and enhanced immunogenicity for vaccine applications through customizable surface chemistry and co-encapsulation with adjuvants. Additionally, the technology supports the co-encapsulation of a diverse range of active pharmaceutical ingredients (APIs), including mRNA, siRNA, tRNA, DNA, antisense oligonucleotides (ASO), proteins, peptides, and small molecules, thereby enabling a versatile approach to treatment.

Furthermore, Optimeos's nanoparticle technology boasts enhanced tissue targeting capabilities, achieved through modular particle assembly that allows for the incorporation of targeting moieties or unique polymers. This feature is complemented by a superior dosing profile, which enables a fivefold increase in payload content, facilitating more efficient disease modification. Overall, Optimeos Life Sciences is positioned to significantly advance the field of RNA and DNA medicine through its cutting-edge delivery platform.

United States

Optimeos Life Sciences is pioneering a novel targeted gene delivery approach to advance medical treatment and patient care.

Optimeos Life Sciences

Company Details